![](https://investorshub.advfn.com/uicon/182506.png?cb=1466612923)
Thursday, July 27, 2017 8:31:49 AM
_______________________________________________________________
AstraZeneca shares plummet 16% on late-stage trial failure; Bristol-Myers shares fall 6% and Merck shares rise 5%
Published: July 27, 2017 8:07 a.m. ET
AstraZeneca PLC AZN, -15.35% shares plummeted as much as 16% in premarket trade Thursday after the company said its cancer drug combination failed to meet its primary endpoint in a late-stage clinical trial. In the AstraZeneca late-stage trial, the combination of the drugs Imfinzi and tremelimumab -- intended for previously-untreated patients with metastatic first-line non-small cell lung cancer -- did not improve progression-free survival compared to the standard of care. The results could have implications for Bristol-Myers Squibb Co.'s BMY, -5.06% cancer drug combination, and the company's shares dropped 6.2% in premarket trade. Meanwhile, shares of cancer drug rival Merck & Co. MRK, +5.08% -- which has a key position in the first-line lung cancer market with cancer drug Keytruda -- rose 5% in premarket trade. For AstraZeneca, "this is a clear disappointment given the large market opportunity," said Leerink Research analyst Seamus Fernandez. "The read-through is an obvious negative read-through for BMY's combo of Opdivo and Yervoy in the ongoing CheckMate-227 trial... While there are several key differences in trial design between MYSTIC and CM-227, they are unlikely to result in meaningfully different outcomes." However, EvercoreISI analyst Umer Raffat was slightly more optimistic, noting that the AstraZeneca trial isn't over yet and also has overall survival as a primary endpoint, with results expected in the first half of next year. "It will be unreasonable to pretend as if nothing has changed on MYSTIC... but I also acknowledge that we shouldn't forget about several [immuno-oncology] trials which have delivered [overall survival] benefit despite not having any [progression-free survival] benefit," Raffat said. AstraZeneca shares have surged 10% over the last three months, Bristol-Myers shares have lifted 0.6% and Merck shares have dropped 1.3%, compared with a 3.7% rise in the S&P 500 SPX, +0.03%
______________________________________________
http://www.marketwatch.com/story/astrazeneca-shares-plummet-16-on-late-stage-trial-failure-bristol-myers-shares-fall-6-and-merck-shares-rise-5-2017-07-27
BMY
Recent BMY News
- Bristol Myers Squibb Elects Michael R. McMullen to Board of Directors • Business Wire • 06/18/2024 08:16:00 PM
- Bristol Myers Squibb Announces Dividend • Business Wire • 06/18/2024 10:59:00 AM
- U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors • Business Wire • 06/13/2024 08:46:00 PM
- Bristol Myers Squibb Announces Opdivo (nivolumab) Plus Yervoy (ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carcinoma in CheckMate -9DW Trial • Business Wire • 06/04/2024 12:00:00 PM
- Bristol Myers Squibb to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference • Business Wire • 06/04/2024 10:59:00 AM
- Bristol Myers Squibb’s Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented at 2024 ASCO® Annual Meeting • Business Wire • 06/03/2024 02:13:00 PM
- Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO® Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer • Business Wire • 06/03/2024 12:00:00 PM
- KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer • Business Wire • 06/01/2024 12:00:00 PM
- U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma • Business Wire • 05/30/2024 03:51:00 PM
- Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma • Business Wire • 05/29/2024 10:59:00 AM
- Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research Platforms • Business Wire • 05/23/2024 09:05:00 PM
- OpenAI and News Corp Seal Partnership, DuPont de Nemours Announces Division, and More News • IH Market News • 05/23/2024 11:40:51 AM
- Bristol Myers Squibb to Present Data at the 2024 American Society of Clinical Psychopharmacology Annual Meeting • Business Wire • 05/23/2024 10:59:00 AM
- Bristol Myers Squibb Announces 10-Year Strategy to Reach More Patients in Low- and Middle-Income Countries • Business Wire • 05/22/2024 10:59:00 AM
- NeoPhore closes oversubscribed Series B extension round with additional funding from Bristol Myers Squibb • PR Newswire (US) • 05/22/2024 07:30:00 AM
- NeoPhore closes oversubscribed Series B extension round with additional funding from Bristol Myers Squibb • PR Newswire (US) • 05/22/2024 07:30:00 AM
- Bristol Myers Squibb, Taye Diggs and Schizophrenia Community Partner to Empower People with Schizophrenia Through Live Your PosSCZible Campaign • Business Wire • 05/21/2024 12:45:00 PM
- Bristol Myers Squibb Announces Updated Action Date by the U.S. Food and Drug Administration for Subcutaneous Nivolumab (nivolumab and hyaluronidase) • Business Wire • 05/21/2024 10:59:00 AM
- New Four-Year Sotyktu (deucravacitinib) Data Demonstrate Durable Response Rates and Consistent Safety in Moderate-to-Severe Plaque Psoriasis • Business Wire • 05/16/2024 02:26:00 PM
- Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma • Business Wire • 05/16/2024 12:57:00 AM
- Arm Sets 2025 Target for AI Chip Development, Amazon and Microsoft Commit Billions to French Investments, and More • IH Market News • 05/13/2024 11:16:03 AM
- Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial • Business Wire • 05/10/2024 08:30:00 PM
- Bristol Myers Squibb to Participate in Upcoming Investor Conferences • Business Wire • 05/07/2024 10:59:00 AM
- European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite... • Business Wire • 05/06/2024 10:59:00 AM
- U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase) • Business Wire • 05/06/2024 10:59:00 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM